Cytokinetics Receives Approval for Myqorzo to Treat Adult oHCM
Cytokinetics announced that the European Commission, EC, has approved Myqorzo, 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, oHCM, in adult patients. Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with Myqorzo reduces cardiac contractility and consequently, left ventricular outflow tract obstruction. "The approval of MYQORZO in the European Union is an important milestone towards bringing this medicine to more patients living with obstructive HCM around the world," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased that the European label allows providers flexibility to determine whether a patient starts treatment at either 5 mg or 10 mg, based on the severity of their baseline LVOT obstruction. We look forward to making MYQORZO available in Europe, beginning with our first launch in Germany in the second quarter of this year."
